Drugplain

ICATIBANT 30 mg/3mL

ICATIBANT · INJECTION · Cipla USA Inc.

No Recall HistoryCurrently in Shortage
Plain English

ICATIBANT is a injection containing icatibant at 30 mg/3mL, taken subcutaneous. Manufactured by Cipla USA Inc..

Key Facts

Brand Name
ICATIBANT
Generic Name
ICATIBANT
NDC Code (Product)
69097-664
Manufacturer
Cipla USA Inc.
Strength
30 mg/3mL
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Marketing Status
Application #
ANDA212446
Marketing Start
07/13/2020

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

hereditary angioedema931 reports
weight increased274 reports
drug ineffective260 reports
weight decreased259 reports
product dose omission issue249 reports
product use issue240 reports
malaise201 reports
headache197 reports
inappropriate schedule of product administration189 reports
covid-19171 reports

Frequently Asked Questions

What is ICATIBANT used for?

ICATIBANT contains ICATIBANT. It is a injection taken subcutaneous. Consult your doctor for specific uses.

Is ICATIBANT a controlled substance?

ICATIBANT is not classified as a controlled substance by the DEA.

What is the generic name for ICATIBANT?

The generic name for ICATIBANT is ICATIBANT. There are 8 other brand versions of ICATIBANT.

What is the NDC code for ICATIBANT 30 mg/3mL?

The NDC (National Drug Code) for ICATIBANT 30 mg/3mL is 69097-664, listed by Cipla USA Inc..

Product NDC

69097-664

Package NDC

69097-664-34

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)